Novel candidates

#Biopharmaceuticals #Biotechnology #Epidemiology #Infectious diseases #Novel candidates

Destiny Pharma publishes landmark XF-73 clinical data  

Destiny Pharma, a UK-based clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, has published landmark XF-73 clinical data in the US peer reviewed journal Infection Control & Hospital Epidemiology.    The paper was published by Dr. Julie Mangino… Read More

#News

#Automation / robotics #Biotechnology #Cell therapy #Novel candidates

Ori Biotech and CTMC accelerate novel cell therapy delivery 

Ori Biotech and the Cell Therapy Manufacturing Center (CTMC) have partnered to accelerate process development, clinical implementation, and commercialisation of novel cell therapies.   The partnership will combine Ori’s technology platform with CTMC’s manufacturing capabilities and, in the first instance, will focus on a cell therapy invented by Dr Sattva Neelapu,… Read More

#Business & Investment #News

#AI #Biotechnology #Drug targets #Novel candidates #Precision medicine

Biotech and precision medicine tie-up addresses unmet cardiac needs 

TARA Biosystems, a biotechnology company using human biology and data for cardiac drug discovery, has collaborated with Scipher Medicine, a precision medicine company. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.   Cardiac laminopathies, associated with mutations in the LMNA gene, can result in… Read More

#News #Trending News

#AI #Drug development #Drug discovery #Novel candidates #Therapeutics

Strategic collaboration could open the door to new world-class medicines

EQRx and Exscientia are collaborating to combine the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates and expand EQRx’s pipeline of novel therapies. This collaboration is focused on creating improvements in the traditional drug discovery and development processes by improving the probability of success… Read More

#News

#Drug discovery #Novel candidates

Tube-dwelling anemone toxins have pharmacological potential

By André Julião, Agência FAPESP Researchers based in Brazil and the US have completed the first-ever mapping exercise to profile the toxins produced by tube-dwelling anemones, or cerianthids, a family of marine animals belonging to the same phylum (Cnidaria) as sea anemones, jellyfish and corals. The analysis revealed that the… Read More

#Editor's Choice #News

#Antibodies #Covid-19 #Novel candidates #Therapeutics

Novel COVID-19 antibody therapy candidates identified by UK biotech consortium

The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody ‘cocktail’. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool… Read More

#Covid-19 #Editor's Choice #News #Trending News